Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,048.42 -23.21 (-0.46%) Dow
38,085.80 -375.12 (-0.98%) Nasdaq
15,611.76 -100.99 (-0.64%) Bitcoin USD
64,690.60 +826.50 (+1.29%) CMC Crypto 200
1,393.80 +11.23 (+0.81%)
GILD Jan 2025 62.500 put
| Previous close | 3.7500 |
| Open | 3.7500 |
| Bid | 4.1000 |
| Ask | 4.2500 |
| Strike | 62.50 |
| Expiry date | 2025-01-17 |
| Day's range | 3.9500 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 886 |
ReutersGilead posts quarterly loss, revenue rises 5%
Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.
Business WireGilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
